	US 11,925,614 B2
	Fatty acid derivatives for treating non-alcoholic steatohepatitis
Hilde Hermansen Steineger, Oslo (NO); David Alan Fraser, Blommenholm (NO); and Tore Skjæret, Oslo (NO)
Assigned to BASF AS, Oslo (NO)
Appl. No. 16/769,659
Filed by BASF AS, Oslo (NO)
PCT Filed Dec. 5, 2018, PCT No. PCT/IB2018/001459 § 371(c)(1), (2) Date Jun. 4, 2020, PCT Pub. No. WO2019/111048, PCT Pub. Date Jun. 13, 2019.
Claims priority of provisional application 62/743,013, filed on Oct. 9, 2018.
Claims priority of application No. 20171944 (NO), filed on Dec. 6, 2017; and application No. 20171945 (NO), filed on Dec. 6, 2017.
Prior Publication US 2021/0177794 A1, Jun. 17, 2021
Int. Cl. A61K 31/202 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01)

CPC A61K 31/202 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01)]

30 Claims

1. A method of reducing fibrosis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of formula (II):

wherein R₁is selected from a C₁₀-C₂₂alkenyl having 3-6 double bonds;

R₂and R₃are the same or different and are selected from the group of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; wherein R₂and R₃can be connected in order to form a cycloalkane like cyclopropane, cyclobutane, cyclopentane or cyclohexane;

X is a carboxylic acid or a derivative thereof; wherein the derivative is a carboxylate, a carboxylic ester, a glyceride, an anhydride, a carboxamide, a phospholipid, or a hydroxymethyl;

or a pharmaceutically acceptable salt, solvate, or solvate of such a salt, thereof;

wherein the subject has non-alcoholic steatohepatitis or alcoholic steatohepatitis; and

wherein the subject has hepatic fibrosis.